Results 111 to 120 of about 43,619 (256)

A rare cause of hemoptysis

open access: yes, 2014
Angiosarcomas are rare, malignant, endothelial-cell tumors of vascular origin that can arise at any body site. They frequently metastasize to the lung, heralded by dyspnea, hemoptysis, chest pain, pneumothoraces, and diffuse pulmonary hemorrhage. However,
Meghan Aversa   +7 more
core   +1 more source

First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial

open access: yesCancer, Volume 132, Issue 11, 1 June 2026.
Envafolimab combined with recombinant human endostatin demonstrates favorable efficacy and tolerable toxicity in non–small cell lung cancer patients. MMP1 and TNFRSF6B may be predictive biomarkers for treatment response. Abstract Background This trial evaluates the efficacy and safety of combining envafolimab and recombinant human endostatin (Rh ...
Changhong Dong   +22 more
wiley   +1 more source

Hemoptysis in renal transplant recipients [Inkstų transplantatų recipientų hemoptizė]

open access: yes, 2021
Background: Hemoptysis is the expectoration of blood from respiratory system. Clinical entities associated with hemoptysis in renal transplant recipients differ from those causing hemoptysis in common population.
Trakas, N.   +9 more
core  

Solitary Neurofibroma of the Hypopharynx: A Case Report

open access: yes
Clinical Case Reports, Volume 14, Issue 6, June 2026.
Matin Ghazizadeh, Vahid Ghasem Amooeian
wiley   +1 more source

Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER

open access: yesCancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background PLCNEC is a rare and highly aggressive lung cancer with a poor prognosis. Multimodal therapy, primarily chemotherapy‐based, is the standard for advanced PLCNEC, but the role of radiotherapy remains unclear. Methods We analyzed 1086 PLCNEC patients receiving chemotherapy from the Surveillance, Epidemiology, and End Results (SEER ...
Yuze Zhao   +5 more
wiley   +1 more source

A Rare Cause of Hemoptysis

open access: yes, 2009
Hemoptysis is a bleeding in the respiratory system together with a cough. Common causes of hemoptysis are bronchitis, lung cancer, bronchiectasis, pulmonary tuberculosis, pulmonary embolism and pneumonia.
Hatipoglu, Osman Nuri   +3 more
core  

Exploring Floristic Diversity and Medicinal Plant Uses in Venda, Limpopo, South Africa

open access: yesFeddes Repertorium, Volume 137, Issue 2, June 2026.
ABSTRACT Plants have been an important source of medicine for thousands of years. To better understand the current diversity and usage of medicinal plants, floristic studies are essential. This report documents an expedition conducted in the Venda region of Limpopo, South Africa. The study was carried out in Shanzha and surrounding villages, as well as
Gurusamy Manikandan   +2 more
wiley   +1 more source

Catamenial hemoptysis [PDF]

open access: yesQJM: An International Journal of Medicine, 2020
C-L, Chen, W-C, Huang, W-C, Cheng
openaire   +2 more sources

Approach to Hemoptysis in the Modern Era

open access: yes, 2017
Hemoptysis is a frequent manifestation of a wide variety of diseases, with mild to life-threatening presentations. The diagnostic workup and the management of severe hemoptysis are often challenging.
Hervé Dutau   +4 more
core   +1 more source

The “5L” framework of diagnostic reasoning: A stepwise scaffold to support clinician educators

open access: yesJournal of Hospital Medicine, Volume 21, Issue 6, Page 665-669, June 2026.
Abstract Diagnostic reasoning (DR) is a core clinical skill, yet its teaching remains variable. We introduce the “5L” framework as a bedside teaching scaffold that gives educators and learners a shared, stepwise set of prompts for DR during individual encounters. By asking, “What's Lethal? What's Likely? What's Logical? What's Lurking?
Olivia Brumfield   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy